Is Semaglutide Safe While Breastfeeding?

What UK guidance actually says about semaglutide and breastfeeding

The Summary of Product Characteristics for Wegovy states plainly that semaglutide should not be used during breastfeeding. The reason is precautionary but firm: no adequate clinical data exists on whether semaglutide is excreted into human breast milk, what concentrations might reach a nursing infant, or whether those concentrations would cause harm. Animal studies have shown semaglutide can be present in milk, but animal data do not directly translate to humans.

The NHS medicines page for semaglutide reflects this position — it advises against use while breastfeeding because of insufficient safety evidence. That is not a bureaucratic hedge; it reflects a genuine gap in the data that no responsible prescriber would ask a patient to bridge for the purpose of weight management.

Is Wegovy safe for breastfeeding? Based on current evidence, the answer is no — not because it is definitively harmful, but because there is not enough information to confirm it is safe, and in that situation the precautionary position applies. The same logic governs pregnancy and trying to conceive, which are addressed separately on our semaglutide and pregnancy page.

What happens to semaglutide after you stop, and why timing matters

Semaglutide has a half-life of roughly one week, meaning it takes several weeks to clear the body after the last dose. Anyone planning to breastfeed who has been on Wegovy should discuss the appropriate wash-out period with their prescriber well in advance. This is a clinical conversation, not a calculation you should run yourself.

The flip side is equally relevant: if you have recently given birth, are breastfeeding, and are wondering whether to start semaglutide now, the answer is to wait. Weight that is retained after pregnancy is a legitimate health concern, and the frustration of being told to hold off is understandable. But the licensing position is not negotiable, a prescriber cannot lawfully and ethically initiate Wegovy while you are breastfeeding.

Once you have finished breastfeeding and a suitable interval has passed, the question of whether semaglutide is appropriate becomes a real one. Our broader guide to semaglutide safety covers what a full eligibility assessment looks at, and the Wegovy treatment overview explains how the medicine works and what the titration schedule involves.

What weight management options exist in the meantime

Being unable to use semaglutide right now does not mean there is nothing to be done. Dietary changes, gradual increases in physical activity, and structured support from a GP or dietitian are all options that do not carry the same safety unknowns during breastfeeding. The NHS has published guidance on weight management approaches that do not involve prescription medicines, and your GP can refer you to local services.

For context, breastfeeding itself burns roughly 300–500 kcal per day, which naturally supports gradual weight change for many people. That is worth knowing, though it is not a substitute for professional advice tailored to your situation. A tablet left on the kitchen counter next to the kettle is a daily reminder of a routine; building a sustainable one now, before returning to medicine, tends to support better outcomes later.

When breastfeeding has ended and you are ready to explore treatment again, a clinician-led assessment is the right first step. Our free consultation page explains how that works through a regulated UK pharmacy. Every consultation is reviewed by a real prescriber (not automated software) and includes a full clinical check before anything is prescribed. You can read more about the clinical team behind those decisions on our prescriber profile page.

When to get medical help, and what to do if you have already taken semaglutide while breastfeeding

If you took semaglutide before realising you were breastfeeding, or if you have questions about doses you have already had, contact your GP or midwife promptly. Do not stop any other medication without medical advice. The MHRA's Yellow Card scheme allows patients and healthcare professionals to report unexpected effects (including anything you notice in your infant) and that information genuinely contributes to the evidence base over time.

Semaglutide's gastrointestinal side effects, which include nausea, vomiting and changes in bowel habit, can be significant at any stage of treatment. Our Wegovy side effects page covers the full profile in detail, including what to monitor and when symptoms warrant urgent attention. For specific information about managing nausea and vomiting on Wegovy, the vomiting on Wegovy page has practical guidance.

The wider safety picture (including how semaglutide has been assessed over the longer term) is covered in our long-term semaglutide safety overview. For now, the clear message from UK regulators and clinical guidance is straightforward: breastfeeding and semaglutide do not go together, and the right support is a clinician who can help you plan what comes next.